Skip to content

Gooreind Pharma

Active
Private limited companyfounded 200421 yrs activeTheo Verellenlaan 70, 2990 Wuustwezel, BelgiumKBO/BCE: BE 0870.403.170
Summary

Gooreind Pharma has been active since 2004 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €390,026 and a net result of €59,344. Equity remains stable across the filed fiscal years (±2% per year). Its solvency ranks better than 62% of 11770 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730Warehousing and support activities for transportation NACE 52310
1 site
Size
€791,241total assets 2025
Staff
4.4 FTE
Equity
€390,026
Profit
€59,344
Turnover not published (abridged schema)
Financial health
93 Excellent Checked score 2025
Bankruptcy chance 12 m
0.1%
Structure
Parent
CATANT · 64.58%
Accounts filed 4 d late0 of 3 deeds read
Why 93- Sector Retail trade (NACE 47)+ Founded in 2004+ Liquidity: current ratio 2.37, cash €100,334+ Equity €390,026 (49.3% of total assets)Show the evidence

Checked score

Score 2025
93 / 100
Excellent
Probability in this band: under 0.55%
Better than 57% of its sector peers (NACE 47, micro)
Performance against the sector, not lower risk
Financial strength · tick = 2024
Strong
Solvency 74+5
equity 49.3% of total assets
Liquidity 55+6
short-term debt 27.3% · cash 12.7%
Profitability 78+1
return on assets 7.5%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.7% (39,919 companies)
Last 24 months 11-2024: 0.1% 12-2024: 0.1%● 0.0% vs 11-2024 01-2025: 0.1%● 0.0% vs 12-2024 02-2025: 0.1%● 0.0% vs 01-2025 03-2025: 0.1%▼ -0.9% vs 02-2025lowest value 04-2025: 0.1%▲ +5.7% vs 03-2025 05-2025: 0.1%▼ -3.6% vs 04-2025 06-2025: 0.1%▲ +20.4% vs 05-2025 07-2025: 0.2%▲ +47.7% vs 06-2025 08-2025: 0.2%▼ -4.7% vs 07-2025 09-2025: 0.2%● 0.0% vs 08-2025 10-2025: 0.2%● 0.0% vs 09-2025 11-2025: 0.2%● 0.0% vs 10-2025 12-2025: 0.2%● 0.0% vs 11-2025 01-2026: 0.2%● 0.0% vs 12-2025 02-2026: 0.2%● 0.0% vs 01-2026 03-2026: 0.2%▼ -1.1% vs 02-2026 04-2026: 0.2%▲ +5.5% vs 03-2026 05-2026: 0.2%▼ -1.6% vs 04-2026 06-2026: 0.2%▲ +8.0% vs 05-2026 07-2026: 0.3%▲ +24.1% vs 06-2026 08-2026: 0.6%▲ +154% vs 07-2026highest value 09-2026: 0.1%▼ -80.9% vs 08-2026 10-2026: 0.1%● 0.0% vs 09-2026
  • Founded in 2004 lowers the probability for this profile
  • Liquidity: current ratio 2.37, cash €100,334 lowers the probability
  • Equity €390,026 (49.3% of total assets) lowers the probability
  • Sector Retail trade (NACE 47) raises the probability
Credit up to €35,000 at 30 days acceptable
Liquidity ample (current ratio 2.37 against 2.09 in 2024; short-term debt: 27.3% and cash: 12.7% of total assets), but 50.7% of the assets are financed with debt.
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 47, micro). Better than this share of them on solvency 64%, liquidity 61%, profitability 68%, growth against the median 38%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 03-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Founded in 2004
In the bankruptcy model this factor lowers the probability for this profile.
KBO
lowers risk · Liquidity: current ratio 2.37, cash €100,334
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
lowers risk · Equity €390,026 (49.3% of total assets)
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
raises risk · Sector Retail trade (NACE 47)
In the bankruptcy model this factor raises the probability.
KBO
neutral · A punctual record breaks
This company filed 8 consecutive financial years on time. The year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 04-08-2026, 4 days late. Weigh it accordingly: a break into the 1-to-90-day band measures 1.41% abnormal legal state, below the 1.66% market average. It is a change in behaviour, not evidence of elevated risk.
NBB · 10 filings
Deviation from the deadline
2025
4 d late
2024
16 d early
2023
8 d early
2022
35 d early
2021
24 d early
2020
36 d early
2019
31 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 21 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 15 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
03-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · abbreviated…
  2. Annual accounts filedfiscal year 2024 · abbreviated…
  3. Annual accounts filedfiscal year 2023 · abbreviated…

Key points

  • Positive: 8 profitable years in a rowprofit 2025: €59,344 8 years View
  • Controlled by CATANT 64.58% View
  • Total assets 20256 fiscal years filed €791,241 View

By topic

Financials

Fiscal year
2025
Total assets
€791,241
Profit
€59,344
Solvency
49.3%
Total assets▼ 10.0%
Net result
20182025
Go to Financials

Timeline

Events
12
Since
2017
Next accounts
by 31-07-2027
  1. 04-08-2026Annual accounts filed
  2. 15-07-2025Annual accounts filed
  3. 23-07-2024Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
06-12-2004
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.